SERVICE

Biosolvix Technique

bt_bb_section_bottom_section_coverage_image

TechniqueBiosolvix Technique

–

BioSolvix Strength

Biosolvix aims to provide safe and ethically sound services for the development of new drugs, focusing on efficacy and toxicity measurements in humans while minimizing harm to animals.

Item Introduction

Biosolvix offers organoids as a solution to enhance the quality of life for both humans and animals..

Organoids are miniature organs created in the laboratory using the differentiation and 3D cultivation of stem cells.

In 2023, the United States FDA abolished the mandatory requirement for animal testing, and organoids gained prominence as an ethical alternative to address the ethical concerns associated with animal experimentation.

This shift away from mandatory animal testing is expected not only in the United States but also globally..

Our company aims to build an organoid panel by transferring organoid technology, establishing methods for producing various tissue-specific organoids and cancer cell organoids. We also strive to develop personalized drug screening, efficacy assessment, and alternative animal testing methods for toxicity evaluation.

Differentiation

Most domestic and international competitors in the organoid field are primarily university-based and tend to be professor-led startups.

Biosolvix, on the other hand, is primarily led by bio-specialized management and distinguishes itself from existing companies by securing standardized organoid technology, enabling a faster path to commercialization..

We also aim to rapidly establish a presence in the organoid market by securing high-quality organoid technology and technology for developing the most similar organs through collaborations with various companies and universities.

Target market

The current organoid market is experiencing rapid growth, with a compound annual growth rate (CAGR) of 22.1%.

The current non-clinical CRO market in South Korea is approximately 500 billion KRW. Our goal is to achieve a 1% market share in the non-clinical CRO market for efficacy and toxicity testing (approximately 5 billion KRW) within the next 3 years.

Furthermore, as the pharmaceutical and biotech industries continue to grow, we believe that if we expand our presence to include efficacy assessment, drug screening, and drug efficacy testing for various venture companies, our revenue growth will increase significantly.

Biosolvix aims to seize the rapidly growing market for alternative animal testing by promoting its services through events like BIO USA and BIO KOREA within the next 3 years.

Our Service

Biosolvix aims to establish animal-free testing services that are most suitable for humans and patients using organoids

http://www.biosolvix.com/wp-content/uploads/2023/07/s_bg_1.png

Organoid banking

http://www.biosolvix.com/wp-content/uploads/2023/07/s_bg_2.png

Cancer Organoid

http://www.biosolvix.com/wp-content/uploads/2023/07/s_bg_3.png

Drug Screening & Toxicity Study

http://www.biosolvix.com/wp-content/uploads/2023/07/s_bg_4.png

Organ on a chip

Your Full Service Lab for Clinical Trials

More About BioSolvix

Opening hours

Mon

9am - 6pm

Tue

9am - 6pm

Wed

9am - 6pm

Thu

9am - 6pm

Fri

9am - 6pm

Sat - Sun

Closed

WRITE USQuotation Request